

STUDIEN & UMFRAGEN 2024

Stand: Mai 2024

KONTAKT

NOGGO Studiengruppe

Tel.: 030 403 6865 30

studies@noggo.de

AGO Studiengruppe

Tel.: 0611 8804 670

office-wiesbaden@ago-ovar.de

NOGGO

Nord-Ostdeutsche Gesellschaft
für Gynäkologische Onkologie e.V.



OVARIAL-, TUBEN- & PERITONEALKARZINOM

Primärtherapie, rekrutierend

NOGGO ov32 – MAKEI V

Randomisierte, prospektive, multizentrische Studie bei Patientinnen mit extrakranialem malignem Keimzelltumor

NOGGO ov53 / ENGOT-ov62 – N-Plus

A Phase II randomized, open label non-inferiority study of Niraparib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completely debulked advanced HRDpositive high-grade ovarian cancer patients in first line therapy

NOGGO ov54 – SCOUT-1

Prospective non-interventional Study to Collect real-world clinical and patient-reported Outcome data in ovarian cancer patients eligible for first-line platinum-based chemotherapy and intended for BRCA/HRD testing

AGO-OVAR 26 – MATAO

Maintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

AGO-OVAR 27 – WoO

Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer

AGO-OVAR 28 / ENGOT-ov57

Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)

Rezidivtherapie, rekrutierend

SUPPORTIVE THERAPIEN

Primärtherapie, rekrutierend

NOGGO S18 – EMRISK

Risikovorhersage-Modell zu chemotherapieinduzierter Übelkeit und Erbrechen bei gynäkologischen Karzinomen

Rezidivtherapie, rekrutierend

NOGGO S15 – FraStrROC

Entwicklung und prospektive Validierung eines Frailty-Scores für chemotherapiebedingte Toxizität beim Ovarialkarzinom

Primär- / Rezidivtherapie, rekrutierend

NOGGO S19 – EXPRESSION VIII

Umfrage zur individuellen Wahrnehmung + Infostand bei „Low-grade“-Ovarialkarzinom und Borderlinetumor

NOGGO S20/ENGOT-gyn4 – EXPRESSION IX

Umfrage für Langzeitüberlebende mit gynäkologischen Tumoren

NOGGO S22/ENGOT-EN16 – EXPRESSION XI

IMPROVE: International Survey for Endometrial Cancer patients: perspective and expectation on therapy and quality of life

Geplante Umfragen

platinsensitiv

NOGGO ov44 – PERCEPTION

Phase-II-Studie zur Bewertung der Wirksamkeit von Pembrolizumab in Kombination mit einer platinbasierten Chemotherapie und als Erhaltungstherapie beim Low-grade-Ovarialkarzinom

ab 2. Linie

NOGGO ov45 – CAROLIN

Nicht-interventionelle Beobachtungsstudie zur Erfassung von Krankheits-, Patientinnen- und Behandlungscharakteristika bei Langzeitüberlebenden mit Eierstockkrebs

ab 1. Linie

NOGGO-ov55 / ENGOT-ov56 – DOVACC

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer

ab 2. Linie

AGO-OVAR 2.34 – MIROVA

A randomized Phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha high recurrent ovarian cancer eligible for platinum-based chemotherapy

ab 2. Linie

AGO-OVAR 2.41 / ENGOT-ov58 – TEDOVA

Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without Pembrolizumab versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patient with controlled disease after platinum-based chemotherapy

2.–3. Linie

platinresistent

NOGGO ov52 / ENGOT-ov51 – MITO33

Randomized Phase III trial on Niraparib-Dostarlimab vs physician's choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: MITO 33 trial

2.–3. Linie

Rezidivtherapie, geplant

AGO-OVAR 2.46 / ENGOT-ov81 – RAMP 301

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

platinsensitiv

NOGGO ov65 / ENGOT-ov79 – REFRaME-O1

A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator's Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)

ab 2. Linie

NOGGO ov66 / ENGOT-ov82 – EvoPAR

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, 3-cohort Study of Saruparib Second-line Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer, who Progressed After First-line PARPi (EvoPAR-Ovarian01)

ab 2. Linie

NOGGO S30 – Expression XVIII

Angst vor Krisen vs. Angst vor Krebs – Internationale Umfrage zum Einfluss von Krisen auf Krebspatientinnen

NOGGO S33 – Expression XX

Breaking Bad News aus Sicht der Patientinnen

MAMMAKARZINOM

Primärtherapie, rekrutierend

NEUE STUDIE IN PLANUNG

ZERVIXKARZINOM, ENDOMETRIUMKARZINOM, UTERINE SARKOME & GYNÄK. TUMORE

Primärtherapie, rekrutierend

AGO-OP.6 – ECLAT

Pelvine und paraaortale LNE bei Patientinnen mit Endometriumkarzinom Stadium I oder II mit hohem Rezidivrisiko

Primär- / Rezidivtherapie, rekrutierend

NOGGO RU1 – REGSA NOGGO / AGO

Prospektive Registerstudie zur Erfassung der Behandlungspraxis von gynäkologischen Sarkomen in der klinischen Routine

Primär- / Rezidivtherapie, geplant

AGO-EN 7 / ENGOT-EN23 – MK-2870-005

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)

AGO-VULVA 1 – PIERCE

Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (PIERCE)

